Rituximab add-on therapy for breakthrough relapsing multiple sclerosis
A 52-week phase II trial
Abstract
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
Information & Authors
Information
Published In
Copyright
Publication History
Notes
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Parenteral anti-B cell therapy for multiple sclerosis: From origins to the creation of the Russian drug divosilimab, Meditsinskiy sovet = Medical Council, 12, (108-112), (2024).https://doi.org/10.21518/ms2024-318
- Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines, Multiple Sclerosis and Related Disorders, 83, (105435), (2024).https://doi.org/10.1016/j.msard.2024.105435
- The Effect of Rituximab on the Cognitive Function of Patients with Relapsing-Remitting Multiple Sclerosis, Clinical Therapeutics, 46, 10, (e1-e5), (2024).https://doi.org/10.1016/j.clinthera.2024.07.011
- Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1060696
- Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab, Basic & Clinical Pharmacology & Toxicology, 133, 5, (550-564), (2023).https://doi.org/10.1111/bcpt.13932
- A safety review of current monoclonal antibodies used to treat multiple sclerosis, Expert Opinion on Drug Safety, 22, 11, (1011-1024), (2023).https://doi.org/10.1080/14740338.2023.2224556
- Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis, Nature Reviews Neurology, 19, 8, (461-476), (2023).https://doi.org/10.1038/s41582-023-00838-7
- Current evidence of rituximab in the treatment of multiple sclerosis, Multiple Sclerosis and Related Disorders, 75, (104729), (2023).https://doi.org/10.1016/j.msard.2023.104729
- Monoclonal antibodies in multiple sclerosis treatment, Translational Neuroimmunology, Volume 8, (191-207), (2023).https://doi.org/10.1016/B978-0-443-18578-6.00011-8
- Efficacy and safety of rituximab in multiple sclerosis: a systematic review and meta-analysis, Acta Neurologica Belgica, 123, 6, (2115-2127), (2023).https://doi.org/10.1007/s13760-023-02329-4
- See more
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.